MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia

References

• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95(11):1399–1420.
   PubMed Web of Science ®Google Scholar
• Cumbo C, Tota G, Anelli L, et al. TP53 in myelodysplastic syndromes: recent biological and clinical findings. Int J Mol Sci. 2020;21(10):3432.
   PubMed Web of Science ®Google Scholar
• Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13(2):83–96.
   PubMed Web of Science ®Google Scholar
• Andreeff M, Kelly KR, Yee K, et al. Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia. Clin Cancer Res. 2016;22(4):868–876.
   PubMed Web of Science ®Google Scholar
• Reis B, Jukofsky L, Chen G, et al. Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. Haematologica. 2016;101(5):e185–e188.
   PubMed Web of Science ®Google Scholar
• Ishizawa J, Nakamaru K, Seki T, et al. Predictive gene signatures determine tumor sensitivity to MDM2 inhibition. Cancer Res. 2018;78(10):2721–2731.
   PubMed Web of Science ®Google Scholar
• Kawata Y, Nagasaka K, Oda K, et al. Effect of murine double-minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys. Cancer Sci. 2020;111(10):3824–3834.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(1):97–108.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Fenaux P, Al-Kali A, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17(4):496–508.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010;116(16):3830–3834.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Patel K, Bueso-Ramos C, et al. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016;7(12):14172–14187.
   PubMedGoogle Scholar
• Lambert JMR, Gorzov P, Veprintsev DB, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell. 2009;15(5):376–388.
   PubMed Web of Science ®Google Scholar
• Sallman DA, DeZern AE, Garcia-Manero G, et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol. 2021;39(14):1584–1594.
   PubMed Web of Science ®Google Scholar
• Tang Y-A, Lin R-K, Tsai Y-T, et al. MDM2 overexpression deregulates the transcriptional control of RB/E2F leading to DNA methyltransferase 3A overexpression in lung cancer. Clin Cancer Res. 2012;18(16):4325–4333.
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Uoto K, Sugimoto Y, et al. Discovery of DS-5272 as a promising candidate: a potent and orally active p53-MDM2 interaction inhibitor. Bioorg Med Chem. 2015;23(10):2360–2367.
   PubMed Web of Science ®Google Scholar
• Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1):11–24.
   PubMed Web of Science ®Google Scholar
• Ganan Gomez I, Ogoti Y, Marchesin M, et al. Effect of azacytidine on the hematopoietic stem and progenitor cell compartments of MDS mouse models: unveiling the mechanisms of remission and relapse. Blood. 2015;126:2852.
   PubMed Web of Science ®Google Scholar
• Chen L, Ye H-L, Zhang G, et al. Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells. PLOS One. 2014;9(1):e85771.
   PubMed Web of Science ®Google Scholar
• Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25(9):1105–1111.
   PubMed Web of Science ®Google Scholar
• Anders S, Pyl PT, Huber W. HTSeq – a python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31(2):166–169.
   PubMed Web of Science ®Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–140.
   PubMed Web of Science ®Google Scholar
• Kim D, Pertea G, Trapnell C, et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14(4):R36.
   PubMed Web of Science ®Google Scholar
• Love M, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Matozaki S. The SKM-1 leukemic cell line established from a patient with progression to myelomonocytic leukemia in myelodysplastic syndrome (MDS)-contribution to better understanding of MDS. Leuk Lymphoma. 1995;17(3–4):335–339.
   PubMed Web of Science ®Google Scholar
• Al-Mawali A, Gillis D, Lewis I. Immunoprofiling of leukemic stem cells CD34+/CD38–/CD123+ delineate FLT3/ITD-positive clones. J Hematol Oncol. 2016;9(1):61.
   PubMedGoogle Scholar
• Walter RB, Appelbaum FR, Estey EH, et al. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119(26):6198–6208.
   PubMed Web of Science ®Google Scholar
• van Rhenen A, Moshaver B, Kelder A, et al. Aberrant marker expression patterns on the CD34 + CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia. 2007;21(8):1700–1707.
   PubMed Web of Science ®Google Scholar
• Pievani A, Biondi M, Tomasoni C, et al. Location first: targeting acute myeloid leukemia within its niche. J Clin Med. 2020;9(5):1513.
   PubMed Web of Science ®Google Scholar
• Meisel M, Hinterleitner R, Pacis A, et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature. 2018;557(7706):580–584.
   PubMed Web of Science ®Google Scholar
• Bosch Jvd, Lübbert M, Verhoef G, et al. The effects of 5-aza-2′-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res. 2004;28(8):785–790.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Lee J-W, Prebet T, et al. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. Br J Haematol. 2014;167(1):62–68.
   PubMed Web of Science ®Google Scholar
• Shastri A, Will B, Steidl U, et al. Stem and progenitor cell alterations in myelodysplastic syndromes. Blood. 2017;129(12):1586–1594.
   PubMed Web of Science ®Google Scholar
• Khong T, Sharkey J, Spencer A. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica. 2008;93(6):860–869.
   PubMed Web of Science ®Google Scholar
• Ball BJ, Famulare CA, Stein EM, et al. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020;4(13):2866–2870.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496–2506.
   PubMed Web of Science ®Google Scholar
• Zhu W-G, Hileman T, Ke Y, et al. 5-aza-2′-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem. 2004;279(15):15161–15166.
   PubMed Web of Science ®Google Scholar
• Cooks T, Harris CC, Oren M. Caught in the cross fire: p53 in inflammation. Carcinogenesis. 2014;35(8):1680–1690.
   PubMed Web of Science ®Google Scholar